- ISIN
- US0167441049
- CUSIP
- 016744104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 21, 2021
Highlights
- Market Cap
- $21.08M
- Enterprise Value
- $1.27M
- EPS (TTM)
- -$0.74
- Total Revenue (TTM)
- $345.00K
- Gross Profit (TTM)
- $320.00K
- EBITDA (TTM)
- -$11.08M
- Year Range
- $0.77 - $2.35
- ROA (TTM)
- -32.21%
- ROE (TTM)
- -162.56%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ALLR Performance Chart
Allarity Therapeutics, Inc. (ALLR) is up 22.2% since the beginning of the year. At $1 per share, ALLR is trading 43.8% below its 52-week high of $2.
Loading charts...
Returns By Period
Allarity Therapeutics, Inc. (ALLR) has returned 22.22% so far this year and 46.67% over the past 12 months.
Allarity Therapeutics, Inc.
- 1D
- -2.94%
- 1M
- -25.42%
- YTD
- 22.22%
- 6M
- 25.71%
- 1Y
- 46.67%
- 3Y*
- -93.26%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
ALLR Monthly Returns History
Based on dividend-adjusted daily data since Dec 21, 2021, ALLR's average daily return is -1.10%, while the average monthly return is -18.83%.
Historically, 20% of months were positive and 80% were negative. The best month was May 2022 with a return of +82.6%, while the worst month was Apr 2024 at -78.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 30 months.
On a daily basis, ALLR closed higher 39% of trading days. The best single day was Aug 26, 2025 with a return of +51.9%, while the worst single day was Jul 6, 2023 at -54.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.41% | -3.00% | 12.37% | 23.85% | 21.48% | -19.51% | 22.22% | ||||||
| 2025 | -4.27% | -28.69% | 17.30% | 28.08% | -27.79% | 16.56% | 2.97% | 48.08% | 2.60% | -8.23% | -8.28% | -18.80% | -7.69% |
| 2024 | -21.14% | -11.04% | -22.12% | -78.91% | -51.50% | -65.44% | -14.51% | -0.27% | -61.25% | -33.65% | -21.43% | 6.36% | -99.65% |
| 2023 | -14.91% | -26.00% | -74.05% | -73.81% | -40.11% | -37.38% | -61.52% | -27.17% | -59.62% | -25.44% | -0.69% | -0.37% | -99.87% |
| 2022 | -21.25% | -48.23% | -51.77% | -24.02% | 82.58% | -53.36% | -9.09% | -2.50% | -5.98% | -49.08% | -19.84% | -34.57% | -97.17% |
| 2021 | -30.14% | -30.14% |
Benchmark Metrics
Allarity Therapeutics, Inc. has an annualized alpha of -94.51%, beta of 0.96, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 21, 2021.
- This stock participated in 257.24% of S&P 500 Index downside but only -164.22% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -94.51%
- Beta
- 0.96
- R²
- 0.02
- Upside Capture
- -164.22%
- Downside Capture
- 257.24%
Return for Risk
Risk / Return Rank
ALLR ranks 62 for risk / return — better than 62% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Allarity Therapeutics, Inc. (ALLR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALLR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.31 | ||
| Sortino ratioReturn per unit of downside risk | -0.86 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.32 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 0.80 | 2.46 | -1.66 |
| Martin ratioReturn relative to average drawdown | 1.42 | 10.92 | -9.50 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Allarity Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Allarity Therapeutics, Inc. was 100.00%, occurring on Apr 9, 2025. The portfolio has not yet recovered.
The current Allarity Therapeutics, Inc. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -100.00%Apr 2025 | 3y 3mo | — | 4y 6moDec 2021 - now |
Drawdown Indicators
| ALLR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -58.88% | -9.10% | -49.78% |
Max Drawdown (3Y)Largest decline over 3 years | -99.99% | -18.90% | -81.09% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -3.21% | -96.79% |
Average DrawdownAverage peak-to-trough decline | -95.87% | -10.71% | -85.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 32.93% | 2.04% | +30.89% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Allarity Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Allarity Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALLR relative to other companies in the Biotechnology industry. Currently, ALLR has a P/S ratio of 58.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALLR in comparison with other companies in the Biotechnology industry. Currently, ALLR has a P/B value of 3.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ALLR
Add Allarity Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ALLR